NEW YORK (TheStreet) -- Facebook (FB) - Get Report and Twitter (TWTR) - Get Report traded lower this week following earnings but LinkedIn (LNKD) investors were hoping the third time would be the charm. It wasn't. 

Initially, shares soared after the company reporting beating on earnings per share and revenue estimates and raised full-year guidance. But it didn't take long for the stock to turn lower, falling over 4% in after-hours trading on Thursday. 

Colin Gillis, senior tech analyst at BGC Financial, has a hold rating and $250 price target on LinkedIn. Speaking during CNBC's "Fast Money" program, he said a big part of the revenue beat came from the company's recent acquisition of Lynda.com. The core business is not driving growth, and for that reason investors sold the stock in the after-hours. Expenses are climbing at a "rapid rate" and user churn was notable in the recent quarter, he added.  

The results were good, as was the guidance, but they weren't great, said Guy Adami, managing director of stockmonster.com. When a stock has a valuation as high as LinkedIn does, the results need to be better than good; they need to be great. 

Steve Grasso, director of institutional sales at Stuart Frankel, called LinkedIn a "no touch." Even though the labor market is improving, LinkedIn is starting to see its growth plateau, he said. Facebook and LinkedIn highlight how poorly Twitter is doing right now, according to Brian Kelly, founder of Brian Kelly Capital. 

Amgen (AMGN) - Get Report also reported earnings after the close but shares moved higher after the company topped EPS and revenue estimates and raised full-year guidance. 

Both Amgen and Gilead Sciences (GILD) - Get Report reported good results, said Karen Finerman, president of Metropolitan Capital Advisors. While the sector is tough to invest in because of valuation, it's got a lot of growth to satisfy investors. 

Amgen is a little different, though, Adami said. Trading at just 17 times forward earnings estimates, the stock isn't that expensive, given its high growth rate and impressive margins. 

One way to offset the risk of owning just one or two biotech stocks is by buying the SPDR Biotech ETF (XBI) - Get Report or the iShares Nasdaq Biotech ETF (IBB) - Get Report, Grasso said. Kelly added he would be a buyer of the IBB ETF on a decline to $340.

Shares of Fiat Chrysler Automobiles (FCAU) - Get Report climbed 7.3% after reporting favorable earnings. Kelly said if the stock can get above $16, a large breakout could ensue. However, Adami and Finerman said they would rather buy Ford (F) - Get Report near current levels. 

The conversation turned to the U.S. dollar. Raoul Pal, publisher of the Global Macro Investor, said the dollar seems likely to climb 20% in 2015 (or another 10%-12% in addition to the year-to-date gains), and another 20% in 2016. As a result, the euro will likely fall to 75 cents to the dollar, significantly lower than where it trades today, with a value of 1 euro being equal to roughly $1.10. 

He also expects the strong dollar to push the price of oil into the $20's. Pal acknowledged that it seems extreme but still completely plausible, especially if demand begins to decline a result of the slowing economy. 

While plenty of investors still like European equities, Pal argued that Germany could be on the verge of dragging the region into a recession. He also called the Chinese economy "a mess" and expects the country to weigh on global growth.

Kelly said China is one of Germany's largest importers, so a China slowdown could most certainly hurt Germany. 

Grasso said to stay long refinery stocks such as Tesoro (TSO) and Valero Energy (VLO) - Get Report, which benefit from lower oil prices. He also pointed out a strong U.S. dollar would be problematic for multinational U.S. companies. 

Adami likes bonds, which should also benefit from a rising U.S. dollar.

Follow TheStreet.com on Twitter and become a fan on Facebook.